



Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes

van Dongen, Joris; Tuin, Aartje; Spiekman, Maroesjka; Jansma, Johan; van der Lei, Berend; Harmsen, Martin

Published in: Journal of tissue engineering and regenerative medicine

DOI: 10.1002/term.2407

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Publication date: 2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): van Dongen, J. A., Tuin, A. J., Spiekman, M., Jansma, J., van der Lei, B., & Harmsen, M. C. (2017). Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review. Journal of tissue engineering and regenerative medicine. DOI: 10.1002/term.2407

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review

Joris A. van Dongen, B.Sc^{1, 2, #}, A. Jorien Tuin, MD^{3, #}, Maroesjka Spiekman, B.Sc¹, Johan Jansma, MD, DMD, PhD³, Berend van der Lei, MD, PhD^{2, 4}, Martin C. Harmsen, PhD^{1,*}

¹ Department of Pathology & Medical Biology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands

² Department of Plastic Surgery, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands

³ Department of Oral & Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

⁴ Bergman Clinics, locations Heerenveen, Zwolle and Groningen, the Netherlands

[#] Authors contributed equally

*Corresponding author

Prof. dr. Martin C. Harmsen, PhD Department of Pathology and Medical Biology University of Groningen University Medical Center Groningen Hanzeplein 1 9713 GZ Groningen Phone: +31.50.361.4776

Fax +31.50.361.9911

Email: m.c.harmsen@umcg.nl



This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/term.2407

Running title

Intraoperative procedures for stromal vascular fraction isolation

Conflict of interest

The authors have no conflict of interest to disclose in relation to the content of this work.

Funding

This study was funded by the University Medical Center Groningen

Abstract

Introduction

Intraoperative application of stromal vascular fraction (SVF) of adipose tissue, requires a fast and efficient isolation procedure of adipose tissue. This review was performed to systematically assess and compare procedures currently used for the intraoperative isolation of cellular SVF (cSVF) and tissue SVF (tSVF) which still contains the extracellular matrix.

Methods

Pubmed, EMBASE and The Cochrane Central Register of controlled trials databases were searched for studies that compare procedures for intraoperative isolation of SVF (searched 28th of September, 2016). Outcomes of interest were cell yield, viability of cells, composition of SVF, duration, cost and procedure characteristics. Procedures were subdivided in procedures resulting in a cSVF or tSVF.

Results

Thirteen out of 3038 studies were included, evaluating eighteen intraoperative isolation procedures, were considered eligible. In general, cSVF and tSVF intraoperative isolation procedures had comparable cell yield, cell viability and SVF composition compared to a non-intraoperative (*i.e. culture lab-based collagenase protocol*) control group within the same studies. The majority of intraoperative isolation procedures are less time consuming than non-intraoperative control groups, however.

Conclusion

Intraoperative isolation procedures are less time-consuming than non-intraoperative control group with similar cell yield, viability of cells and composition of SVF and therefore more suitable for use in the clinic. Nevertheless, none of the intraoperative isolation procedures could be designated as preferred procedure to isolate SVF.

Keywords: Lipografting, Stromal vascular fraction, Adipose derived stem/stromal cells, Non-enzymatic isolation, Enzymatic isolation, Collagenase

1. Introduction

Adipose tissue seems to be an outstanding source for regenerative therapies, since it is an easy accessible source for adipose-derived stem or stromal cells (ASCs). Adipose tissue can easily be harvested with liposuction, a low risk procedure that can be performed under local anesthesia. Several clinical trials have been published using ASCs for soft tissue reconstruction (Tanikawa et al. 2013), cardiac repair (Perin et al. 2014), pulmonary repair (Tzouvelekis et al. 2013) and cartilage repair (Jo et al. 2014). All these trials show promising results for future use of ASCs in tissue repair and regeneration.

To harvest ASCs, adipose tissue or lipoaspirate is subjected to enzymatic dissociation followed by several centrifugation steps (Bourin et al. 2013), which is a relative long-lasting procedure that cannot be performed during surgery. The cell population obtained by this enzymatic digestion and centrifugation is the stromal vascular fraction (SVF), containing ASCs, endothelial cells, supra-adventitial cells, lymphocytes and pericytes (Eto et al. 2009, Bourin et al. 2013). ASCs in vivo are characterized as CD31min/CD45min/CD34pos/CD90pos/CD105low cells (Yoshimura et al. 2006). After isolation, the SVF can either be used directly in clinical procedures or can be cultured to increase the number of cells before using them in the clinic (Gir et al., Suga et al. 2007). In case of cell culturing, only ASCs and their precursor cells (supra-adventitial cells and pericytes) are able to adhere and survive (Zuk et al. 2001, Zimmerlin et al. 2010). Upon passaging in vitro, the phenotype of ASCs starts to deviate from their in vivo phenotype (Spiekman et al., 2016): in this process CD34 surface expression is lost, while CD105 expression is up-regulated to mention a few (Yoshimura et al. 2006, Corselli et al. 2012). Alternatively,

administration of the enzymatically prepared vascular stromal fraction of adipose tissue might have a therapeutic capacity that is similar to cultured ASCs. Although, no formal scientific evidence exists, the consensus is, that the therapeutic benefit of SVF predominantly relies on the abundantly present ASCs.

The current protocol to isolate and culture ASCs from adipose tissue involves enzymatic digestion with collagenase. This is a laborious and time consuming protocol and requires a specialized culture lab (Good Manufacturing Practice facilities (cGMP)), which is not available in most peripheral hospitals (Gimble et al. 2010). Therefore, intraoperative procedures for SVF isolation are warranted, in particular systems that do not employ enzymatic treatment, such as mechanical dissociation.

At present, several (commercial) procedures are available for intraoperative isolation of SVF (Aronowitz et al. 2015, Oberbauer et al. 2015). These intraoperative isolation procedures differ in various aspects: isolation of a single cell SVF (cellular SVF (cSVF)) resulting in a pellet with hardly any volume or isolation of SVF cells containing intact cell-cell communications (tissue SVF (tSVF). Most of the enzymatic intraoperative isolation procedures result in a cSVF, because of the loss of cell-cell communications and extracellular matrix. In most of the non-enzymatic intraoperative isolation procedures the cell-cell communications remain intact, resulting in an end product with more volume (tSVF). Different studies assessed the cell yield and phenotype of the isolated cSVF or tSVF of the various intraoperative isolation procedures compared to other intraoperative (commercial) procedures or to the gold standard for SVF isolation (non-intraoperative culture lab-based collagenase protocols which require cGMP facilities for clinical use, referred to as 'nonintraoperative isolation protocol'). Recently, new intraoperative isolation procedures are introduced and tested. It is not clear yet if intraoperative isolation procedures generate a similar quality and quantity of SVF as non-intraoperative isolation protocols. Next to this, the distinction between end products of intraoperative isolation procedures, e.g. cSVF and tSVF have never been studied. Therefore, a systematic review was performed to assess the efficacy of intraoperative isolation procedures of human SVF based on number of cells, cell viability and composition of SVF. In addition, duration and costs of the intraoperative isolation procedures were compared.

2. Material & Methods

2.1. Protocol and registration

This study was performed using the PRISMA protocol (Moher et al. 2009). The search strategy for this systematic review was based on a Population, Intervention, Comparison, and Outcome (PICO) framework (Schardt et al. 2007). The study was not registered.

2.2. Eligibility criteria

Studies were included when at least two different types of intraoperative isolation procedures or one intraoperative isolation procedure with a non-intraoperative isolation protocol were assessed using human adipose tissue to isolate SVF. Studies need to use the adipose fraction of lipoaspirate. Studies only evaluating centrifugation forces, sonication or red blood cell (RBC) lysis buffer were excluded. Studies focusing on processing methods of adipose tissue for the use in fat grafting were excluded as well as case reports, case series and reviews. Searches were not limited to date, language or publication status (Table 1).

2.3. Information sources and search

Pubmed, EMBASE (OvidSP) and The Cochrane Central Register of controlled trials databases were searched (searched 28th September, 2016). The search was restricted to human studies. The search terms (Table 2) were based on three components: (P) adipose stromal cell, adipose stem cell, stromal vascular fraction, autologous progenitor cell, or regenerative cell in combination with (I) cell separation, isolation, dissociation, digestion, emulsification, isolation system, cell concentrator and finally connected with (C) enzymatic, non-enzymatic, or mechanical.

2.4. Study selection and data collection process

Two authors (JAD, AJT) selected studies independently based on the eligibility criteria. Inconsistencies were discussed during a consensus meeting. In case of disagreement, the senior author (MCH) gave a binding verdict.

2.5. Data items

Search term was partly based on a Population, Intervention, Comparison, Outcome (PICO) framework. Outcomes of interest were not included in the search term. For this review the outcomes of interest were cell yield, viability of the nucleated cells, composition of the SVF and duration, cost and characteristics of the intraoperative isolation procedures. Effect sizes were calculated on cell yield and viability in studies with a comparison of intraoperative isolation procedures versus regular non-intraoperative isolation protocols. Differences in harvesting procedure were not taken into account.

2.6. Risk of bias in individual studies

It is known that the quality of ASCs depends on age and harvest location of the donor (Engels et al. 2013, Dos-Anjos Vilaboa et al. 2014, Di Taranto et al. 2015, Maredziak et al. 2016). The inclusion of young healthy patients may positively affect the results. Therefore, detailed information about demographics are described in this review.

2.7. Summary measurements

Effect sizes were calculated of the outcome variables cell yield and percentage of viable nucleated cells from cSVF between enzymatic intraoperative isolation procedures and non-intraoperative isolation protocols (gold standard). The following effect size formula was used: effect size = (difference in mean outcomes between enzymatic intraoperative isolation procedures and gold standard) / (standard deviation of the gold standard). Studies which presented results in mean and standard deviation were analyzed. Intraoperative isolation procedures focusing on tSVF instead of cSVF were not taken into account in the effect size of cell yield, because of different start volumes of lipoaspirate and end volumes of tSVF.

2.8. Synthesis of results

In some studies, derivate numbers of graphs are used when the actual number of outcomes was not given. Cell types within the SVF can be distinguished based on CD marker expression or immuno-staining. To compare SVF compositions between different studies and to compare intraoperative procedures with their control (*i.e.* non-intraoperative protocols or other intraoperative procedures) in the same study, only CD marker expression was used. Studies evaluating a single CD marker expression to analyze different cell types were seen as insufficient distinctive and were excluded. Cells were divided into two major groups: CD45min (adipose tissue-

derived) and CD45pos (blood derived) cells to analyze the expression of stromal cells, pericytes, vascular endothelial cells/endothelial progenitor cells, endothelial cells, lymphocytes, leukocytes and hematopoietic stem cells. All other cells are placed in the category: other cell types. The CD34pos/CD146pos population is excluded from analysis because of the inability to discriminate between progenitor pericytes and progenitor endothelial cells (Bianchi et al. 2013).

2.9. Risk of bias across studies

Included studies could present different outcome variables related to SVF analysis. There is a risk that studies did not present a full SVF characterization and thereby bias their results. In order to provide an overview of the used outcome variables per study, a Modified IFATS/ISCT Index Score was used (see 2.10). The risk of publication bias of positive results might be expected in those articles were the authors have benefits in the investigated products. Disclosure agreements were reviewed for each study.

2.10. Modified IFATS/ISCT Index Score for the measurement of adipose tissuederived stromal vascular fraction

Studies were assessed based on the reported outcome variables. The assessment of quality was evaluated based on the position statement of the International Federation of Adipose Therapeutics and Science (IFATS) and the International Society of Cellular Therapy (ISCT) (Bourin et al. 2013). The IFATS and ISCTS proposed guidelines to develop reproducible standardized endpoints and methods to characterize ASCs and SVF cells. For each of the following characterization methods a grade was given by the authors (JAD, AJT) to an article if the characterization was carried out: viability of nucleated cells, flow cytometry of SVF cells, flow cytometry of ASCs (CD13, CD29, CD31, CD34, CD44, CD45, CD73, CD90, CD105, CD235a), proliferation and frequency (CFU-F) and functional assays (adipogenic, osteogenic and chondrogenic differentiation assays) of ASCs. The maximum score in case of a full characterization was 5.

3. Results

3.1. Included studies

A total of 3038 studies were identified after database searching. 2955 articles were excluded after abstract screening. 59 full text studies were assessed on eligibility criteria. Fourteen studies were excluded based on the use of a non-intraoperative protocol for isolation as experimental method (Yoshimura et al. 2006, Jiang et al. 2007, Pilgaard et al. 2008, Vykoukal et al. 2008, Al Battah et al. 2011, Fink et al. 2011, Condé-Green and Lamblet 2012, Okura et al. 2012, Carvalho et al. 2013, Escobedo-Lucea et al. 2013, Siciliano et al. 2013, Chen et al. 2014, Doi et al. 2014, Seaman et al. 2015). Seven studies described isolation protocols in general but gave no results (Hicok and Hedrick, Bernacki et al. 2008, Dubois et al. 2008, Yu et al. 2011, Zachar et al. 2011, Buehrer and Cheatham 2013, Zhu et al. 2013). Seven studies were excluded based on the lack of a control group (*i.e.* non-intraoperative isolation protocols or other intraoperative isolation procedures) (Zuk et al. 2001, Zeng et al. 2013, Dos-Anjos Vilaboa et al. 2014, Inoue et al. 2014, Sadighi et al. 2014, Van Pham et al. 2014, Raposio et al. 2016). Four studies were excluded based on their study design (Kim 2014, Marincola 2014, Aronowitz and Hakakian 2015, Bertheuil and Chaput 2015). Three studies were excluded based on the use of culture methods to isolate ASCs, because culture methods are incompatible with intraoperative applications (Wu et al. 2012, Busser et al. 2014, Priya et al. 2014). Four studies used only centrifugation, centrifugation or RBC lysis buffer as isolation protocol and were thereby excluded (Baptista et al. 2009, Markarian et al. 2014, Raposio et al. 2014, Amirkhani et al. 2016). Three studies used the blood saline fraction of lipoaspirate and were thereby excluded (Francis et al. 2010, Shah et al. 2013, Cicione et al. 2016). Four studies did not describe an outcome of interest (Reshak et al. 2013, Fraser et al. 2014, Yi et al. 2014, Aronowitz et al. 2015). Four additional studies were identified through other sources (Fig. 1). Thus, thirteen studies with eighteen intraoperative isolation procedures remained for analysis.

3.2. Study characteristics

In total, 93 subjects were enrolled in the thirteen studies. Nine studies reported gender of which 95% was female (n=58). Nine studies reported the mean age or age variance of the subjects and ten other studies described the use of infiltration (Table 1, supplemental content). No meta-analysis could be performed because the metrics and outcomes were too diverse.

3. 3. Characteristics of the intraoperative isolation procedures

All intraoperative isolation procedures are divided into two categories: enzymatic and non-enzymatic procedures resulting in cSVF and tSVF respectively (Table 3A and table 3B). Eight of the eighteen intraoperative isolation procedures were based on enzymatic digestion and ten isolation procedures were based on non-enzymatic procedures. Two non-enzymatic procedures, the Residual tissue of emulsified fat procedure and the Fractionation of adipose tissue procedure, are named differently, but are almost identical. One intraoperative isolation procedure, the Filtrated fluid of emulsified fat, is a combined procedure of two other intraoperative isolation procedures *i.e.* the Fractionation of adipose tissue procedure and the Nanofat procedure (Tonnard et al. 2013, Mashiko et al. 2016, van Dongen et al. 2016).

3.3.1 Start volume versus end product

The Automated isolation system, GID SVF2, Lipokit system and Multi station are enzymatic intraoperative isolation procedure that resulted in large average amounts of SVF (7.2 ml – 20 ml), suggesting inefficient enzymatic digestions (SundarRaj et al. 2015, Aronowitz et al. 2016). The non-enzymatic intraoperative isolation procedures resulted in larger end volumes than only a pellet. Prior the Lipogems procedure, 130 ml of adipose tissue can be obtained to mechanical dissociate to 100 ml of lipoaspirate. Hence, this a reduction of the volume of 1.3 times, suggesting an inefficient mechanical dissociation to our opinion (Bianchi et al. 2013). In contrast, the Fractionation of adipose tissue procedure resulted in a 10.4-fold volume reduction (van Dongen et al. 2016). For all other intraoperative isolation procedures, no data is mentioned about the end volume of the lipoaspirate (Table 3A and table 3B).

3.3.2 Duration and costs

Duration of the intraoperative isolation procedures varied from 5 seconds to 133 minutes (n=12). Isolation with the Automated isolation system was the longest intraoperative isolation procedure (SundarRaj et al. 2015). Shuffling lipoaspirate 5 or 30 times through a luer-to-luer lock syringe will take 5 or 30 seconds respectively and were therefore the fastest procedures (Osinga et al. 2015). In general, the tested non-enzymatic procedures take less time than the enzymatic procedures (Table 3A and table 3B).

The costs of only enzymatic procedures Celution system (2013: \$1950 and 2016: \$2400), CHA-station (\$710), Multi station (2013: \$460 and 2016: \$250), Lipokit system (2013: \$530 and 2016: \$450) and GID SVF2 (\$1000) are mentioned, the enzymatic Celution system being the most expensive (Aronowitz and Ellenhorn 2013, Aronowitz et al. 2016). No data of non-enzymatic intraoperative procedures were available (Table 3A and table 3B).

3.4. Cell yield

Thirteen studies evaluated the cell yield of eighteen different intraoperative isolation procedures (Millan, Lin et al. 2008, Guven et al. 2012, Aronowitz and Ellenhorn 2013, Bianchi et al. 2013, Doi et al. 2013, Tonnard et al. 2013, Domenis et al. 2015, Osinga et al. 2015, SundarRaj et al. 2015, Aronowitz et al. 2016, Mashiko et al. 2016, van Dongen et al. 2016) (Table 2A and table 2B, supplemental content). The reported cell yield after those different procedures varied between $0.19 - 11.7 \times 10^5$ cells per ml in enzymatic intraoperative isolation procedures and between 1.8 – 22.6 x 10⁵ cells per ml in non-enzymatic intraoperative isolation procedures. Nonenzymatic intraoperative procedures yielded higher number of cells since the cell yield was based on 1ml of end volume, whereas the enzymatic intraoperative isolation cell yield was based on the obtained pellet per 1 ml start volume of lipoaspirate. Of the enzymatic intraoperative isolation procedures, the Celution system, Multi station and Lipokit system were evaluated by more than one group of authors (Lin et al. 2008, Aronowitz and Ellenhorn 2013, Domenis et al. 2015, Aronowitz et al. 2016). Interestingly, obvious different yields were seen using the same procedure in different studies (Lin et al. 2008, Aronowitz and Ellenhorn 2013, Domenis et al. 2015, Aronowitz et al. 2016). Reproducibility is thereby questioned in our opinion. The cell yield using the enzymatic Celution system was significantly higher as compared to the Lipokit system (p=0.004), the Multi station (p=0.049) and CHA-station (p<0.001) (Aronowitz and Ellenhorn 2013). In contrast, Domenis et al. did not find a statistical difference between the enzymatic Celution system and Lipokit system. Moreover, Aronowitz et al. again compared the enzymatic Celution system with the Lipokit system and Multi station. This time, Multi station and the Lipokit system resulted in significant more cells as compared to the Celution system (p<0.05) (Aronowitz et al. 2016).

In the non-enzymatic intraoperative isolation procedures, the Squeezed fat, Residual fluid of emulsified fat and Fractionation of fat procedures resulted in the relative highest cell yields per ml harvested lipoaspirate (Mashiko et al. 2016, van Dongen et al. 2016). Non-enzymatic intraoperative isolation procedures such as shuffling (5 times and 30 times), the Nanofat procedure and Fastem did not mention the begin and end volumes, so the relative yield by isolation cannot be calculated (Tonnard et al. 2013, Domenis et al. 2015, Osinga et al. 2015). Osinga et al, reported that most of the adipocytes remain intact after shuffling 5 or even 30 times (Osinga et al. 2015). Consequently, to our opinion, the effect of shuffling only cannot be stated as an isolation procedure. We deem it possible that the lipoaspirate after both two procedures did not differ from the initial lipoaspirate obtained at the start of the procedure. However, the benefit might be at a different level, because shuffling does improve the injectability of lipoaspirates as shown by Tonnard et al. (Tonnard et al. 2013).

More interesting than comparing intraoperative isolation procedures evaluated in different studies might be the comparison between an intraoperative isolation procedure and a non-intraoperative isolation protocol (gold standard) starting from the same lipoaspirate. Six studies reported the results of such comparisons (Table 4A) (Millan , Lin et al. 2008, Guven et al. 2012, Doi et al. 2013, Domenis et al. 2015, SundarRaj et al. 2015). The Automated isolation system and Tissue genesis cell isolation system resulted in the same cell yield as the non-intraoperative isolation protocol control (effect size, respectively, 0.07 and 0.00) (Doi et al. 2013, SundarRaj et al. 2015). Sepax isolated a higher cell yield compared to a non-intraoperative isolation protocol (effect size 1.11) (Table 4A) (Guven et al. 2012). Lower cell yield was seen after using the Lipokit system compared to the non-intraoperative isolation protocol control (effect size -0.52) (Domenis et al. 2015). Interestingly, the highest positive as well as the most negative effect sizes were seen with the enzymatic Celution system related to regular isolation with a non-intraoperative isolation protocol (Lin et al. 2008, Domenis et al. 2015).

3.5. Viability of nucleated cells

Eight studies described viabilities from 39% to 98% of nucleated cells in the SVF. No big differences in viability were seen between enzymatic and non-enzymatic intraoperative isolation procedures. The Filtrated fluid of emulsified fat procedure showed the lowest viability (Mashiko et al. 2016), while the Automated isolation system showed the highest viability of nucleated cells of 98% after isolation (Table 2A and table 2B, supplemental content) (SundarRaj et al. 2015). Three enzymatic and three non-enzymatic intraoperative isolation procedures were compared to a non-intraoperative isolation protocol regarding the viability of nucleated cells (Table 4B) (Lin et al. 2008, Doi et al. 2013, SundarRaj et al. 2015). The viability of five intraoperative isolation procedures was comparable to their non-intraoperative isolation protocol controls; the effect sizes were close to zero in many studies (Table 4B). Only the Filtrated fluid of emulsified fat procedure showed an effect size of -45.4 (Mashiko et al. 2016). In general, viability did not differ between non-intraoperative isolation protocols and the individual intraoperative isolation procedures tested.

3.6. Composition of stromal vascular fractions

The SVF compositions is reported in nine studies evaluating six enzymatic procedures and three non-enzymatic procedures. The stromal cell population is larger in the SVF isolated by the enzymatic Celution system, Sepax and Tissue genesis cell isolation system and the non-enzymatic Residual of emulsified fat and Squeezed fat procedures compared to other intraoperative isolation procedures (Guven et al. 2012, Aronowitz and Ellenhorn 2013, Doi et al. 2013, Mashiko et al. 2016) (Table 5, supplemental content). The percentage of stromal cell population of the SVF isolated by the enzymatic Celution system only differs with 25.2% between two studies (Aronowitz and Ellenhorn 2013, Domenis et al. 2015) and 32.8% between two other studies, both evaluated by Aronowitz et al. (Aronowitz and Ellenhorn 2013, Aronowitz et al. 2016). In general, non-enzymatic procedures yielded same amounts of CD31min/CD34pos stromal cells.

The stromal cell population, including pericytes, ASCs and supra-adventitial cells, are the most important cell types in regenerative therapies because of their paracrine effect and multi-lineage differentiation capacity (Zuk et al. 2001, Pawitan 2014).

Pericytes defined using other CD markers than to define the stromal cell population are placed separately in the table. The enzymatic Celution system evaluated by Lin et al. resulted in the lowest percentage of pericytes in the SVF (0.8%), but used more than three CD markers to detect pericytes (Lin et al. 2008). SundarRaj et al. resulted in a higher percentage (2.0%) of pericytes in SVF obtained by the Automated isolation system, but used only two CD markers to determine the pericyte population and other cell types (SundarRaj et al. 2015). The use of multiple CD markers results in a more specific population than the use of less CD markers and so a lower percentage of that specific cell type *e.g.* pericytes (Bianchi et al. 2013). Bianchi et al. used CD34min/CD146pos/CD90pos to detect the pericyte-like population in the SVF and isolated the highest percentage of pericytes using the non-enzymatic Lipogems procedure as compared to other intraoperative isolation procedures (Bianchi et al. 2013). However, Bianchi et al. mostly used other combinations of CD markers in comparison to other studies (Bianchi et al. 2013). This renders their SVF composition incomparable with SVF compositions obtained by other intraoperative isolation procedures.

The enzymatic procedures: Automated isolation system, Tissue genesis cell isolation system and Sepax isolated more endothelial progenitor cells in comparison to other intraoperative isolation procedures (Guven et al. 2012, Doi et al. 2013, SundarRaj et al. 2015). Nonetheless, more endothelial progenitor cells were not corresponding to less stromal cells or pericytes. In all differently obtained SVF, the origin of large numbers of cells remains unidentified. This is partly because not every study identified both adipose tissue-derived and blood-derived cell types, but probably not every subpopulation of all cell types is already known as well.

When donor variability is neutralized by the use of the same lipoaspirate, intraoperative isolation procedures resulted in different SVF compositions. Lipogems isolated significantly more pericytes and stromal cells than the non-intraoperative isolation protocol control (p<0.05) (Bianchi et al. 2013) (Fig. 2). The enzymatic Celution system resulted in significantly more endothelial progenitor cells in comparison with the CHA-system, Lipokit system and Multi station, which is not necessarily preferred (p=0.003) (Aronowitz and Ellenhorn 2013). All other intraoperative isolation procedures compared with non-intraoperative isolation protocols showed no significant differences.

3.7. Modified IFATS/ISCT Index Score for the measurement of adipose tissuederived stromal vascular fraction

Modified IFATS/ISCT index scores ranged from 1 to 4.6 out of 5. Güven et al. scored 4.6 and presented the most complete characterization of the SVF and ASCs (Guven et al. 2012) (Table 5). Tonnard et al. scored 2 points, but had only used CD34 as a marker to identify a subpopulation in the SVF (Tonnard et al. 2013). Two studies used other methods than flow cytometry to determine the composition of SVF (Osinga et al. 2015, van Dongen et al. 2016). No studies were excluded based on a low number of outcomes of interest measured by the modified IFATS/ISCT Index Score, because five out of thirteen studies scored less than half of the possible points given. This high number of low scores given to studies underlines the need for standardization.

3.8 Disclosure agreements of included articles

A disclosure agreement of support by the manufacturer was provided in five of the thirteen studies (Lin et al. 2008, Guven et al. 2012, Aronowitz and Ellenhorn 2013, Bianchi et al. 2013, Doi et al. 2013) (Table 6, supplemental content). The company, which was mostly involved in the studies, was Cytori, the manufacturer of the enzymatic Celution system.

4. Discussion

Grafting of lipoaspirates and of SVF in particular, is a rapidly evolving treatment modality for scars and other skin defects, arthritis, neuropathy, diabetic ulcers to mention a few. Many of these, initially small scale, single center studies, are on the verge of expansion to multicenter placebo-controlled double-blind randomized clinical trials. An important prerequisite is the use of an efficient and standardized intraoperative isolation procedure of SVF. This systematic review shows that none of these procedures supersedes other procedures in terms of cell yield, viability and SVF composition while being time and cost efficient too when analyzed using the same lipoaspirate. However, three intraoperative isolation procedures (shuffling 5 times, shuffling 30 times and Lipogems) showed only a minimal reduction of the volume of lipoaspirate, implicating that most of the adipocytes still are intact. Consequently, these three procedures are methods of processing rather than isolation procedures (Bianchi et al. 2013, Osinga et al. 2015). Moreover, there is a wide variation in cell yield, viability of cells and composition of SVF when all

intraoperative isolation procedures are compared together. Study characteristics showed small and varied sample sizes regarding the number, sex and age of the donors. It is known that the cell yield and viability of SVF differ among donors, depending on age, harvest location and co-morbidities, such as obesity, of the donors (Engels et al. 2013, Dos-Anjos Vilaboa et al. 2014, Di Taranto et al. 2015, Maredziak et al. 2016, Pachon-Pena et al. 2016). This interdonor variability is a possible explanation for the variations found between several studies. To avoid variation bias, isolation procedures should be investigated using identical lipoaspirates in the same study. There are, however, differences between nonenzymatic and enzymatic isolated SVFs on a different level. Non-enzymatic isolation procedures resulted in larger volumes (tSVF) than the resulting pellets (cSVF) after enzymatic intraoperative isolation procedures. Because the final products of both types of isolation procedures are different, the clinical purpose of the use of SVF is an important factor which isolation procedure suits best. In some cases, such as the intra-articular injection of SVF in temporomandibular joints requires very small volumes, whereas the end volume of SVF enriched lipofilling is less relevant. Isolation procedures of SVF of adipose tissue are based on reduction of large volume containing tissue or cells, such as ECM and/or adipocytes to concentrate the stromal vascular fraction. Non-enzymatic isolation of SVF results in a smaller volume of adipose tissue containing intact ECM and cell-cell communications between SVF cells (tSVF), because the shear forces are too low to disrupt cell to cell and cell to ECM adhesions (Lin et al. 2008, Corselli et al. 2012). Therefore, the tissue structure of lipoaspirate is still intact in the tSVF. Enzymatic procedures, however, likely result in a single cell cSVF, because enzymes likely disrupt all cell-cell interactions and ECM (Fig. 3) (Aronowitz et al. 2015). This is may not happen in the Automated isolation system, GID SVF2, Lipokit system and Multi station, possibly due to insufficient enzymatic digestion (SundarRaj et al. 2015, Aronowitz et al. 2016).

Clinical use of tSVF has several advantages over the use of cSVF in different clinical applications of regenerative medicine. It is well known that single cells migrate within 24 hours after application (Parvizi and Harmsen 2015). The ECM, containing a microvasculature structure, might function as a natural scaffold for cells like ASCs and most likely also augments rapid vascularization and reperfusion. This will probably increase cell retention rates after injection and enhance clinical effects. In case of early scar formation, wound healing, or organ fibrosis, tSVF might

therefore be more an appropriate therapy, which implicates that non-enzymatic procedures are more suitable as compared to enzymatic isolation procedures. In case of excessive pre-existing scar formation, the ECM in the SVF might not be appropriate and therefore the application of a cSVF or ASCs might be more eligible. ASCs could remodel excessive scar formation by immunomodulation or instruction of resident cells.

Characterization of subpopulations in the SVF depends upon selection of appropriate markers. Selection of an insufficient number of markers will give a disfigured image of the actual SVF composition (Fig. 3). SVF of adipose tissue can be divided into two major subpopulations based on the expression of CD45, which is a hematopoietic cell marker: adipose derived (CD45min) and blood derived (CD45pos) (Yoshimura et al. 2006). Adipose derived cell populations can be divided into endothelial cells (CD31pos) and stromal cells (CD31min) (Yoshimura et al. 2006). Three important subpopulations of the stromal cell population (CD45min/CD31min) are supra-adventitial cells: CD34pos/CD146min, pericytes: CD34pos/min/CD146pos and ASCs: CD34pos/CD90pos/CD105low (Yoshimura et al. 2006, Zimmerlin et al. 2010, Corselli et al. 2012, Corselli et al. 2013). Supraadventitial cells and pericytes are both identified as precursor cells of ASCs, although there remains some controversy about this item (Lin et al. 2008, Traktuev et al. 2008, Zimmerlin et al. 2010, Corselli et al. 2012). Ideally, to discriminate between those three cell types within the CD45min/CD31min subpopulation, CD146 and/or CD90 markers should be used additionally. However, in most studies two CD markers or inappropriate combinations of CD markers have been used to determine cell types; only Lin et al. used all the aforementioned combinations (Lin et al. 2008). Because Lin et al. focus mainly on blood derived cells and not on the stromal cell population or pericytes, this did not affect their results. Doi et al. ascribed CD31min/CD34min/CD45min to the pericyte population, so therefore the CD34pos pericytes will be missed (Doi et al. 2013). SundarRaj et al. and Güven et al. used CD34pos/CD31min to determine the number of ASCs (Guven et al. 2012, SundarRaj et al. 2015), while pericytes and supra-adventitial cells also express CD34. Therefore, the number of ASCs contains pericytes and supra-adventitial cells as well (Yoshimura et al. 2006, Zimmerlin et al. 2010). To cover pericytes, supra-adventitial cells and ASCs, Domenis et al., Aronowitz et al. and Mashiko et al. used CD34pos/CD31min/CD45min to determine the stromal cell population (Aronowitz and Ellenhorn 2013, Domenis et al. 2015, Aronowitz et al. 2016, Mashiko et al. 2016). CD34pos is frequently used as a marker to describe cells with stem cell characteristics in both hematopoietic and non-hematopoietic stem cells (Suga et al. 2009). The differences in use of CD marker expression to determine pericytes and the stromal cell population might be a possible explanation for the large variations found in SVF between different studies. No solid conclusions could be made about which isolation procedure generates the most stromal cells or pericytes.

Unfortunately, a limited number of commercially available intraoperative SVF isolation procedures not yet have reached scientific validation at an acceptable level. The American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS) published a position statement in 2012 on fat grafting and stem cells (Eaves et al. 2012). All specialized equipment for the use of stem cell extraction should be fully verified regarding efficacy and safety before use in clinical settings. In 2013, the IFATS and ICTS proposed guidelines with standardized endpoints and methods to verify and compare SVF isolation procedures (Bourin et al. 2013). None of the included studies fully verified their isolation procedure according to these IFATS and ICTS guidelines. Moreover, viability was measured in different ways among studies (e.g. directly on obtained SVF or after an extra non-intraoperative isolation protocol) and lipoaspirate was processed differently prior to isolation (*e.g.* centrifugation or decantation). For those reasons, we propose new adjusted IFATS and ICTS guidelines to validate intraoperative isolation procedures (Fig. 3). All intraoperative isolation procedures should be validated using centrifuged adipose tissue to determine the actual volume of lipoaspirate prior to isolation. It is known that increased centrifugal forces have a harmful effect on the viability of fat grafts (Xie et al. 2010, Tuin et al. 2016). However, the use of centrifuged adipose tissue is necessary to determine the actual cell yield after an isolation procedure. Furthermore, cell viability of tSVF should be determined directly on tSVF, instead of using an extra non-intraoperative isolation protocol which possibly results in more cell damage. However, the proposed adjusted standardized endpoints and methods by IFATS and ICTS are time-consuming and expensive since it requires cultured ASCs. In order to quickly verify isolation procedures intraoperatively during clinical trials, the end product of non-enzymatic intraoperative isolation procedures should be centrifuged to separate the oily fraction from the tSVF and pellet fraction based on density. For enzymatic intraoperative isolation

procedures, microscopy can be used to visualize single cells. In this way, isolation procedures can be quickly evaluated during clinical trials.

A large number of SVF isolation procedures without applying a full verification according to the IFATS and ICTS guidelines is available (Oberbauer et al. 2015). Oberbauer et al. presented a narrative overview of enzymatic and non-enzymatic intraoperative SVF isolation procedures (Oberbauer et al. 2015). In twenty-one out of thirty (both enzymatic as well as non-enzymatic) intraoperative isolation procedures reported in their study, there was a lack of verification data. In two studies intraoperative isolation procedures without scientific evidence *e.g.* viability of SVF, flow cytometry of SVF cells and ASCs, were used to treat patients. One study used SVF obtained by ultrasonic cavitation to treat patients with migraine and tension headache (Bright et al. 2014). Another study used SVF in combination with platelet rich plasma for meniscus repair (Pak et al. 2014). Hence, it cannot be guaranteed that the isolation procedures indeed isolate SVF, which is clinical safe for use. It seems that the use of most SVF isolation procedures with its concomitant clinical application is far ahead of a sound scientific base upon which these procedures should be used.

Moreover, the clinical safety of isolated SVF or ASCs is not clear yet, especially regarding clinical use in patients with any kind of malignancy. It is demonstrated, in vitro, that ASCs influence growth, progression and metastasis of cancer cell lines through e.g. promoting angiogenesis and differentiation of ASCs into carcinoma-associated fibroblasts (Freese et al. 2015). Zimmerlin et al. showed in vitro that ASCs influence growth of active malign cell lines, but this is not seen in latent cancer cell lines (Zimmerlin et al. 2011). Clinical data suggest that the use of isolated SVF or ASCs is safe in patients without an oncological history (Charvet et al. 2015). In vitro studies often use higher concentrations of ASCs as compared to clinical studies and this might be the cause of differences found between in vitro and in vivo studies (Charvet et al. 2015). However, to test clinical safety it is important to reach scientific validation of the commercially available procedures at an acceptable level. In this review it become clear that the reproducibility of the procedures as well as characterization of the SVF had shortcomings. If this is reached, further scientific research with proper controls with regard to the clinical effect and safety of SVF or ASCs are definitely wanted.

5. Conclusion

There is no evidence thus far that any intraoperative isolation procedure could be designated as preferred procedure for isolating SVF. However, three isolation procedures are rather processing techniques than isolation procedures. Enzymatic and non-enzymatic procedures had comparable results as it comes to cell yield, viability, and SVF composition. Non-enzymatic isolation procedures end products resulted had greater volumes (tSVF) than the pellets (cSVF) of the enzymatic isolation procedures. The results of intraoperative isolation procedures are comparable with those of the gold standard, the collagenase based non-intraoperative isolation procedures are less time-consuming, but as efficient as the non-intraoperative isolation protocol, the use of intraoperative isolation procedures seems to be more suitable for clinical purposes. However, only small sample sizes have been used to validate the isolation procedures at an acceptable level. Regarding to this review, this level is not yet reached by many procedures.

6. Acknowledgement

We thank prof. dr. A. Vissink (Department of Oral & Maxillofacial Surgery, University of Groningen and University Medical Center Groningen) for his contribution during the preparation of this manuscript.

Accep

References

Al Battah, F., J. De Kock, E. Ramboer, A. Heymans, T. Vanhaecke, V. Rogiers and S. Snykers (2011). "Evaluation of the multipotent character of human adipose tissuederived stem cells isolated by Ficoll gradient centrifugation and red blood cell lysis treatment." *Toxicol In Vitro* **25**(6): 1224-1230.

Amirkhani, M. A., R. Mohseni, M. Soleimani, A. Shoae-Hassani and M. A. Nilforoushzadeh (2016). "A rapid sonication based method for preparation of stromal vascular fraction and mesenchymal stem cells from fat tissue." *Bioimpacts* **6**(2): 99-104.

Aronowitz, J. A. and J. D. Ellenhorn (2013). "Adipose stromal vascular fraction isolation: a head-to-head comparison of four commercial cell separation systems." *Plast Reconstr Surg* **132**(6): 932e-939e.

Aronowitz, J. A. and C. S. Hakakian (2015). "A novel and effective strategy for the isolation of adipose-derived stem cells: minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy." *Plast Reconstr Surg* **135**(2): 454e.

Aronowitz, J. A., R. A. Lockhart and C. S. Hakakian (2015). "Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue." *Springerplus* **4**: 713.

Aronowitz, J. A., R. A. Lockhart, C. S. Hakakian and Z. E. Birnbaum (2016). "Adipose Stromal Vascular Fraction Isolation: A Head-to-Head Comparison of 4 Cell Separation Systems #2." *Ann Plast Surg* **77**(3): 354-362.

Aronowitz, J. A., R. A. Lockhart, C. S. Hakakian and K. C. Hicok (2015). "Clinical Safety of Stromal Vascular Fraction Separation at the Point of Care." *Ann Plast Surg* **75**(6): 666-671.

Baptista, L. S., R. J. do Amaral, R. B. Carias, M. Aniceto, C. Claudio-da-Silva and R. Borojevic (2009). "An alternative method for the isolation of mesenchymal stromal cells derived from lipoaspirate samples." *Cytotherapy* **11**(6): 706-715.

Bernacki, S. H., M. E. Wall and E. G. Loboa (2008). "Isolation of human mesenchymal stem cells from bone and adipose tissue." *Methods Cell Biol* **86**: 257-278.

Bertheuil, N. and B. Chaput (2015). "A novel and effective strategy for the isolation of adipose-derived stem cells: minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy." *Plast Reconstr Surg* **135**(2): 454e-455e.

Bianchi, F., M. Maioli, E. Leonardi, E. Olivi, G. Pasquinelli, S. Valente, A. J. Mendez, C. Ricordi, M. Raffaini, C. Tremolada and C. Ventura (2013). "A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates." *Cell Transplant* **22**(11): 2063-2077.

Bourin, P., B. A. Bunnell, L. Casteilla, M. Dominici, A. J. Katz, K. L. March, H. Redl, J. P. Rubin, K. Yoshimura and J. M. Gimble (2013). "Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)." *Cytotherapy* **15**(6): 641-648.

Bright, R., M. Bright, P. Bright, S. Hayne and W. D. Thomas (2014). "Migraine and tension-type headache treated with stromal vascular fraction: a case series." *J Med Case Rep* **8**: 237.

Buehrer, B. M. and B. Cheatham (2013). "Isolation and characterization of human adipose-derived stem cells for use in tissue engineering." *Methods Mol Biol* **1001**: 1-11.

Busser, H., C. De Bruyn, F. Urbain, M. Najar, K. Pieters, G. Raicevic, N. Meuleman, D. Bron and L. Lagneaux (2014). "Isolation of adipose-derived stromal cells without enzymatic treatment: expansion, phenotypical, and functional characterization." *Stem Cells Dev* **23**(19): 2390-2400.

Carvalho, P. P., J. M. Gimble, I. R. Dias, M. E. Gomes and R. L. Reis (2013). "Xenofree enzymatic products for the isolation of human adipose-derived stromal/stem cells." *Tissue Eng Part C Methods* **19**(6): 473-478.

Charvet, H. J., H. Orbay, M. S. Wong and D. E. Sahar (2015). "The Oncologic Safety of Breast Fat Grafting and Contradictions Between Basic Science and Clinical Studies: A Systematic Review of the Recent Literature." *Ann Plast Surg* **75**(4): 471-479.

Chen, S. Y., M. Mahabole, E. Horesh, S. Wester, J. L. Goldberg and S. C. Tseng (2014). "Isolation and characterization of mesenchymal progenitor cells from human orbital adipose tissue." *Invest Ophthalmol Vis Sci* **55**(8): 4842-4852.

Cicione, C., G. Di Taranto, M. Barba, M. A. Isgro, A. D'Alessio, D. Cervelli, F. V. Sciarretta, S. Pelo, F. Michetti and W. Lattanzi (2016). "In Vitro Validation of a Closed Device Enabling the Purification of the Fluid Portion of Liposuction Aspirates." *Plast Reconstr Surg* **137**(4): 1157-1167.

Condé-Green, A. and H. Lamblet (2012). "Immediate cell-supplemented lipotransfer (iCSL)." *European Journal of Plastic Surgery* **35**(5): 373-378.

Corselli, M., C. W. Chen, B. Sun, S. Yap, J. P. Rubin and B. Peault (2012). "The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells." *Stem Cells Dev* **21**(8): 1299-1308.

Corselli, M., M. Crisan, I. R. Murray, C. C. West, J. Scholes, F. Codrea, N. Khan and B. Peault (2013). "Identification of perivascular mesenchymal stromal/stem cells by flow cytometry." *Cytometry A* **83**(8): 714-720.

Di Taranto, G., C. Cicione, G. Visconti, M. A. Isgro, M. Barba, E. Di Stasio, E. Stigliano, C. Bernardini, F. Michetti, M. Salgarello and W. Lattanzi (2015). "Qualitative and quantitative differences of adipose-derived stromal cells from superficial and deep subcutaneous lipoaspirates: a matter of fat." *Cytotherapy* **17**(8): 1076-1089.

Doi, K., S. Kuno, A. Kobayashi, T. Hamabuchi, H. Kato, K. Kinoshita, H. Eto, N. Aoi and K. Yoshimura (2014). "Enrichment isolation of adipose-derived stem/stromal cells from the liquid portion of liposuction aspirates with the use of an adherent column." *Cytotherapy* **16**(3): 381-391.

Doi, K., S. Tanaka, H. Iida, H. Eto, H. Kato, N. Aoi, S. Kuno, T. Hirohi and K. Yoshimura (2013). "Stromal vascular fraction isolated from lipo-aspirates using an automated processing system: bench and bed analysis." *J Tissue Eng Regen Med* **7**(11): 864-870.

Domenis, R., L. Lazzaro, S. Calabrese, D. Mangoni, A. Gallelli, E. Bourkoula, I. Manini, N. Bergamin, B. Toffoletto, C. A. Beltrami, A. P. Beltrami, D. Cesselli and P. C. Parodi (2015). "Adipose tissue derived stem cells: in vitro and in vivo analysis of a standard and three commercially available cell-assisted lipotransfer techniques." *Stem Cell Res Ther* **6**: 2.

Dos-Anjos Vilaboa, S., M. Navarro-Palou and R. Llull (2014). "Age influence on stromal vascular fraction cell yield obtained from human lipoaspirates." *Cytotherapy* **16**(8): 1092-1097.

Dubois, S. G., E. Z. Floyd, S. Zvonic, G. Kilroy, X. Wu, S. Carling, Y. D. Halvorsen, E. Ravussin and J. M. Gimble (2008). "Isolation of human adipose-derived stem cells from biopsies and liposuction specimens." *Methods Mol Biol* **449**: 69-79.

Eaves, F. F., 3rd, P. C. Haeck and R. J. Rohrich (2012). "ASAPS/ASPS Position statement on stem cells and fat grafting." *Plast Reconstr Surg* **129**(1): 285-287.

Engels, P. E., M. Tremp, P. J. Kingham, P. G. di Summa, R. D. Largo, D. J. Schaefer and D. F. Kalbermatten (2013). "Harvest site influences the growth properties of adipose derived stem cells." *Cytotechnology* **65**(3): 437-445.

Escobedo-Lucea, C., C. Bellver, C. Gandia, A. Sanz-Garcia, F. J. Esteban, V. Mirabet, G. Forte, I. Moreno, M. Lezameta, A. Ayuso-Sacido and J. M. Garcia-Verdugo (2013). "A xenogeneic-free protocol for isolation and expansion of human adipose stem cells for clinical uses." *PLoS One* **8**(7): e67870.

Eto, H., H. Suga, D. Matsumoto, K. Inoue, N. Aoi, H. Kato, J. Araki and K. Yoshimura (2009). "Characterization of structure and cellular components of aspirated and excised adipose tissue." *Plast Reconstr Surg* **124**(4): 1087-1097.

Fink, T., J. G. Rasmussen, P. Lund, L. Pilgaard, K. Soballe and V. Zachar (2011). "Isolation and expansion of adipose-derived stem cells for tissue engineering." *Front Biosci (Elite Ed)* **3**: 256-263.

Francis, M. P., P. C. Sachs, L. W. Elmore and S. E. Holt (2010). "Isolating adiposederived mesenchymal stem cells from lipoaspirate blood and saline fraction." *Organogenesis* **6**(1): 11-14.

Fraser, J. K., K. C. Hicok, R. Shanahan, M. Zhu, S. Miller and D. M. Arm (2014). "The Celution® system: Automated processing of adipose-derived regenerative cells in a functionally closed system." *Advances in Wound Care* **3**(1): 38-45.

Freese, K. E., L. Kokai, R. P. Edwards, B. J. Philips, M. A. Sheikh, J. Kelley, J. Comerci, K. G. Marra, J. P. Rubin and F. Linkov (2015). "Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review." *Cancer Res* **75**(7): 1161-1168.

Gimble, J. M., F. Guilak and B. A. Bunnell (2010). "Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells." *Stem Cell Res Ther* **1**(2): 19.

Gir, P., S. A. Oni G Fau - Brown, A. Brown Sa Fau - Mojallal, R. J. Mojallal A Fau - Rohrich and R. J. Rohrich "Human adipose stem cells: current clinical applications." (1529-4242 (Electronic)).

Guven, S., M. Karagianni, M. Schwalbe, S. Schreiner, J. Farhadi, S. Bula, K. Bieback, I. Martin and A. Scherberich (2012). "Validation of an automated procedure to isolate human adipose tissue-derived cells by using the Sepax(R) technology." *Tissue Eng Part C Methods* **18**(8): 575-582.

Hicok, K. C. and M. H. Hedrick "Automated isolation and processing of adiposederived stem and regenerative cells." (1940-6029 (Electronic)).

Inoue, K. I., H. Nomura, R. Sohma, K. Akimoto, N. Kobayashi, T. Kamai, O. Yamas, I. Taguchi, H. Asato, T. Inoue, O. Mitsumori, H. Iwaguro and K. I. Yoshida (2014). "Feasibility of exploiting Celution[™] system in autologous cell therapy in Dokkyo medical university hospital: Safety and reproducibility." *Dokkyo Journal of Medical Sciences* **41**(1): 7-12.

Jiang, Y., L. Q. Han, Z. Y. Zhu, L. P. Xiao and Z. Liu (2007). "Isolating culture and osteogenic potential of human adipose derived-stromal cells." *Journal of Clinical Rehabilitative Tissue Engineering Research* **11**(37): 7381-7384.

Jo, C. H., Y. G. Lee, W. H. Shin, H. Kim, J. W. Chai, E. C. Jeong, J. E. Kim, H. Shim, J. S. Shin, I. S. Shin, J. C. Ra, S. Oh and K. S. Yoon (2014). "Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial." *Stem Cells* **32**(5): 1254-1266.

Kim, S. K. (2014). "Adipose stromal vascular fraction isolation: a head-to-head comparison of four commercial cell separation systems." *Plast Reconstr Surg* **133**(6): 889e.

Lin, G., M. Garcia, H. Ning, L. Banie, Y. L. Guo, T. F. Lue and C. S. Lin (2008). "Defining stem and progenitor cells within adipose tissue." *Stem Cells Dev* **17**(6): 1053-1063.

Lin, K., Y. Matsubara, Y. Masuda, K. Togashi, T. Ohno, T. Tamura, Y. Toyoshima, K. Sugimachi, M. Toyoda, H. Marc and A. Douglas (2008). "Characterization of adipose tissue-derived cells isolated with the Celution system." *Cytotherapy* **10**(4): 417-426.

Maredziak, M., K. Marycz, K. A. Tomaszewski, K. Kornicka and B. M. Henry (2016). "The Influence of Aging on the Regenerative Potential of Human Adipose Derived Mesenchymal Stem Cells." *Stem Cells Int* **2016**: 2152435.

Marincola, F. M. (2014). "Expression of concern: Clinical use of dieletrophoresis separation for live adipose derived stem cells." *J Transl Med* **12**: 297.

Markarian, C. F., G. Z. Frey, M. D. Silveira, E. M. Chem, A. R. Milani, P. B. Ely, A. P. Horn, N. B. Nardi and M. Camassola (2014). "Isolation of adipose-derived stem cells: a comparison among different methods." *Biotechnol Lett* **36**(4): 693-702.

Mashiko, T., S. H. Wu, J. Feng, K. Kanayama, K. Kinoshita, A. Sunaga, M. Narushima and K. Yoshimura (2016). "Mechanical micronization of lipoaspirates: squeeze and emulsification techniques." *Plast Reconstr Surg*.

Millan, A. "Comparison Between Collagenase Adipose Digestion and StromaCell Mechanical Dissociation for Mesenchymal Stem Cell Separation "*McNar Scholar Journal* **15**.

Moher, D., A. Liberati, J. Tetzlaff and D. G. Altman (2009). "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement." *Open Med* **3**(3): e123-130.

Oberbauer, E., C. Steffenhagen, C. Wurzer, C. Gabriel, H. Redl and S. Wolbank (2015). "Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art." *Cell Regen (Lond)* **4**: 7.

Okura, H., A. Saga, M. Soeda, A. Ichinose and A. Matsuyama (2012). "Adipose tissue-derived multi-lineage progenitor cells as a promising tool for in situ stem cell therapy." *Current Tissue Engineering* **1**(1): 54-62.

Osinga, R., N. R. Menzi, L. A. Tchang, D. Caviezel, D. F. Kalbermatten, I. Martin, D. J. Schaefer, A. Scherberich and R. D. Largo (2015). "Effects of intersyringe processing on adipose tissue and its cellular components: implications in autologous fat grafting." *Plast Reconstr Surg* **135**(6): 1618-1628.

Pachon-Pena, G., C. Serena, M. Ejarque, J. Petriz, X. Duran, W. Oliva-Olivera, R. Simo, F. J. Tinahones, S. Fernandez-Veledo and J. Vendrell (2016). "Obesity Determines the Immunophenotypic Profile and Functional Characteristics of Human Mesenchymal Stem Cells From Adipose Tissue." *Stem Cells Transl Med* **5**(4): 464-475.

Pak, J., J. H. Lee and S. H. Lee (2014). "Regenerative repair of damaged meniscus with autologous adipose tissue-derived stem cells." *Biomed Res Int* **2014**: 436029.

Parvizi, M. and M. C. Harmsen (2015). "Therapeutic Prospect of Adipose-Derived Stromal Cells for the Treatment of Abdominal Aortic Aneurysm." *Stem Cells Dev* **24**(13): 1493-1505.

Pawitan, J. A. (2014). "Prospect of stem cell conditioned medium in regenerative medicine." *Biomed Res Int* **2014**: 965849.

Perin, E. C., R. Sanz-Ruiz, P. L. Sanchez, J. Lasso, R. Perez-Cano, J. C. Alonso-Farto, E. Perez-David, M. E. Fernandez-Santos, P. W. Serruys, H. J. Duckers, J. Kastrup, S. Chamuleau, Y. Zheng, G. V. Silva, J. T. Willerson and F. Fernandez-Aviles (2014). "Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE Trial." *Am Heart J* **168**(1): 88-95.e82.

Pilgaard, L., P. Lund, J. G. Rasmussen, T. Fink and V. Zachar (2008). "Comparative analysis of highly defined proteases for the isolation of adipose tissue-derived stem cells." *Regen Med* **3**(5): 705-715.

Priya, N., S. Sarcar, A. S. Majumdar and S. SundarRaj (2014). "Explant culture: a simple, reproducible, efficient and economic technique for isolation of mesenchymal stromal cells from human adipose tissue and lipoaspirate." *J Tissue Eng Regen Med* **8**(9): 706-716.

Raposio, E., G. Caruana, S. Bonomini and G. Libondi (2014). "A novel and effective strategy for the isolation of adipose-derived stem cells: minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy." *Plast Reconstr Surg* **133**(6): 1406-1409.

Raposio, E., G. Caruana, M. Petrella, S. Bonomini and M. P. Grieco (2016). "A Standardized Method of Isolating Adipose-Derived Stem Cells for Clinical Applications." *Ann Plast Surg* **76**(1): 124-126.

Reshak, A. H., M. M. Shahimin and F. Buang (2013). "Comparative study on human and bovine AT-SC isolation methods." *Prog Biophys Mol Biol* **113**(2): 295-298.

Sadighi, S., A. Khoshzban, A. H. Tavakoli, R. K. Semnani, Z. Sobhani and N. D. Majidabad (2014). "Isolation, amplification and identification of mesenchymal stem cells derived from human adipose tissue." *Tehran University Medical Journal* **72**(1): 27-32.

Schardt, C., M. B. Adams, T. Owens, S. Keitz and P. Fontelo (2007). "Utilization of the PICO framework to improve searching PubMed for clinical questions." *BMC Med Inform Decis Mak* **7**: 16.

Seaman, S. A., S. C. Tannan, Y. Cao, S. M. Peirce and K. Y. Lin (2015). "Differential Effects of Processing Time and Duration of Collagenase Digestion on Human and Murine Fat Grafts." *Plast Reconstr Surg* **136**(2): 189e-199e.

Shah, F. S., X. Wu, M. Dietrich, J. Rood and J. M. Gimble (2013). "A non-enzymatic method for isolating human adipose tissue-derived stromal stem cells." *Cytotherapy* **15**(8): 979-985.

Siciliano, C., M. Ibrahim, G. Scafetta, C. Napoletano, G. Mangino, L. Pierelli, G. Frati and E. De Falco (2013). "Optimization of the isolation and expansion method of human mediastinal-adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate." *Cytotechnology* **67**(1): 165-174.

Spiekman, M., J.A. van Dongen, J. Willemsen, D. Hoppe, B. van der Lei, M.C. Harmsen. 2016. "The power of fat - emerging concepts for fibrotic scar treatment." *Journal of Tissue Engineering and Regenerative Medicine. In press*

Suga, H., D. Matsumoto, H. Eto, K. Inoue, N. Aoi, H. Kato, J. Araki and K. Yoshimura (2009). "Functional implications of CD34 expression in human adipose-derived stem/progenitor cells." *Stem Cells Dev* **18**(8): 1201-1210.

Suga, H., T. Shigeura, D. Matsumoto, K. Inoue, H. Kato, N. Aoi, S. Murase, K. Sato, K. Gonda, I. Koshima and K. Yoshimura (2007). "Rapid expansion of human adipose-derived stromal cells preserving multipotency." *Cytotherapy* **9**(8): 738-745.

SundarRaj, S., A. Deshmukh, N. Priya, V. S. Krishnan, M. Cherat and A. S. Majumdar (2015). "Development of a System and Method for Automated Isolation of Stromal Vascular Fraction from Adipose Tissue Lipoaspirate." *Stem Cells International* **2015**.

Tanikawa, D. Y., M. Aguena, D. F. Bueno, M. R. Passos-Bueno and N. Alonso (2013). "Fat grafts supplemented with adipose-derived stromal cells in the rehabilitation of patients with craniofacial microsomia." *Plast Reconstr Surg* **132**(1): 141-152.

Tonnard, P., A. Verpaele, G. Peeters, M. Hamdi, M. Cornelissen and H. Declercq (2013). "Nanofat grafting: basic research and clinical applications." *Plast Reconstr Surg* **132**(4): 1017-1026.

Traktuev, D. O., S. Merfeld-Clauss, J. Li, M. Kolonin, W. Arap, R. Pasqualini, B. H. Johnstone and K. L. March (2008). "A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks." *Circ Res* **102**(1): 77-85.

Tuin, A. J., P. N. Domerchie, R. H. Schepers, J. C. Willemsen, P. U. Dijkstra, F. K. Spijkervet, A. Vissink and J. Jansma (2016). "What is the current optimal fat grafting processing technique? A systematic review." *J Craniomaxillofac Surg* **44**(1): 45-55.

Tzouvelekis, A., V. Paspaliaris, G. Koliakos, P. Ntolios, E. Bouros, A. Oikonomou, A. Zissimopoulos, N. Boussios, B. Dardzinski, D. Gritzalis, A. Antoniadis, M. Froudarakis, G. Kolios and D. Bouros (2013). "A prospective, non-randomized, no placebo-controlled, phase lb clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis." *J Transl Med* **11**: 171.

van Dongen, J. A., H. P. Stevens, M. Parvizi, B. van der Lei and M. C. Harmsen (2016). "The fractionation of adipose tissue procedure to obtain stromal vascular fractions for regenerative purposes." *Wound Repair Regen*.

Van Pham, P., N. B. Vu, N. L. C. Phan, D. M. Le, N. C. Truong, N. H. Truong, K. H. T. Bui and N. K. Phan (2014). "Good manufacturing practice-compliant isolation and culture of human adipose derived stem cells." *Biomedical Research and Therapy* **1**(4).

Vykoukal, J., D. M. Vykoukal, S. Freyberg, E. U. Alt and P. R. Gascoyne (2008). "Enrichment of putative stem cells from adipose tissue using dielectrophoretic fieldflow fractionation." *Lab Chip* **8**(8): 1386-1393.

Wu, C. H., F. K. Lee, S. Suresh Kumar, Q. D. Ling, Y. Chang, Y. Chang, H. C. Wang, H. Chen, D. C. Chen, S. T. Hsu and A. Higuchi (2012). "The isolation and differentiation of human adipose-derived stem cells using membrane filtration." *Biomaterials* **33**(33): 8228-8239.

Xie, Y., D. Zheng, Q. Li, Y. Chen, H. Lei and L. L. Pu (2010). "The effect of centrifugation on viability of fat grafts: an evaluation with the glucose transport test." *J Plast Reconstr Aesthet Surg* **63**(3): 482-487.

Yi, T., W. K. Kim, J. S. Choi, S. Y. Song, J. Han, J. H. Kim, W. S. Kim, S. G. Park, H. J. Lee, Y. K. Cho, S. J. Hwang, S. U. Song and J. H. Sung (2014). "Isolation of adipose-derived stem cells by using a subfractionation culturing method." *Expert Opin Biol Ther* **14**(11): 1551-1560.

Yoshimura, K., T. Shigeura, D. Matsumoto, T. Sato, Y. Takaki, E. Aiba-Kojima, K. Sato, K. Inoue, T. Nagase, I. Koshima and K. Gonda (2006). "Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates." *J Cell Physiol* **208**(1): 64-76.

Yu, G., Z. E. Floyd, X. Wu, Y. D. Halvorsen and J. M. Gimble (2011). "Isolation of human adipose-derived stem cells from lipoaspirates." *Methods Mol Biol* **702**: 17-27.

Zachar, V., J. G. Rasmussen and T. Fink (2011). "Isolation and growth of adipose tissue-derived stem cells." *Methods Mol Biol* **698**: 37-49.

Zeng, G., K. Lai, J. Li, Y. Zou, H. Huang, J. Liang, X. Tang, J. Wei and P. Zhang (2013). "A rapid and efficient method for primary culture of human adipose-derived stem cells." *Organogenesis* **9**(4): 287-295.

Zhu, M., S. Heydarkhan-Hagvall, M. Hedrick, P. Benhaim and P. Zuk (2013). "Manual isolation of adipose-derived stem cells from human lipoaspirates." *J Vis Exp*(79): e50585.

Zimmerlin, L., A. D. Donnenberg, J. P. Rubin, P. Basse, R. J. Landreneau and V. S. Donnenberg (2011). "Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates." *Tissue Eng Part A* **17**(1-2): 93-106.

Zimmerlin, L., V. S. Donnenberg, M. E. Pfeifer, E. M. Meyer, B. Peault, J. P. Rubin and A. D. Donnenberg (2010). "Stromal vascular progenitors in adult human adipose tissue." *Cytometry A* **77**(1): 22-30.

Zuk, P. A., M. Zhu, H. Mizuno, J. Huang, J. W. Futrell, A. J. Katz, P. Benhaim, H. P. Lorenz and M. H. Hedrick (2001). "Multilineage cells from human adipose tissue: implications for cell-based therapies." *Tissue Eng* **7**(2): 211-228.

Accepted A




Figure 1.






Figure 2. SVF composition (CD marker) of procedures comparing an intraoperative isolation procedure with a non-intraoperative isolation protocol or with other intraoperative isolation procedures within one study. Stromal cell population (CD31min/CD34pos) consists of supra-adventitial cells, ASCs and pericytes, only pericytes defined CD31min/CD146pos, as CD31min/CD34min/pos or CD34min/CD146pos/CD90pos are placed separately in the table. Endothelial cells and vascular/progenitor endothelial cells are described as respectively, CD31pos/CD34min and CD31pos/CD34pos. No exact data described in text by Aronowitz et al., Bianchi et al., Domenis et al., Güven et al. and Mashiko et al., data is extracted from figures by authors JAD and AJT. AIS Automated Isolation System; CHA-station (CHA-Biotech); CYT Celution System Enzymatic (Cytori); FAST Fastem Corios (Corios); GID SVF2 (GID Europe); LIPOK Lipokit System (Medi-khan); PNC Multi station (PNC); REF Residual tissue of emulsified fat; SEPAX Sepax (Biosafe); SF Squeezed fat; Tissue Genesis Cell Isolation System (Tissue Genesis)




Figure 3. A) Schematic overview of enzymatic versus non-enzymatic intraoperative isolation and characterization of the obtained cSVF or tSVF. **B)** Legend of figure 3A.



Table 1. Inclusion and e	exclusion criteria
--------------------------	--------------------

Inclusion criteria	Exclusion criteria
Clinical trials	Case reports
Comparative studies	Case series
Full text available	Reviews
All languages	Letters to editor
Human studies	Non-comparative studies
	No full text available
≥2 different types of SVF	Processing methods for fat grafting
isolation procedures	Protocols using centrifugation or RBC lysis buffer only
1 SVF isolation procedure	Mesenchymal cells derived from other source than adipose tissue
compared with control	Blood saline fraction used instead of adipose fraction of the
group	lipoaspirate
Intraoperative procedures	Laboratory based enzyme protocols as experimental group
	No outcome of interest: SVF composition (CD markers), cell yield,
	viability of SVF
ted	
4	

Table 2. Specific search terms of databases

Search term Pubmed:

((((Adipose Tissue [Mesh] OR Adipocytes [Mesh] OR Fat [tiab] OR Lipoaspirate* [tiab])) AND (Cell separation [Mesh] OR Isolat* [tiab] OR Dissociat* [tiab] OR Emulsification [tiab] OR Concentrat* [tiab] OR Digest* [tiab] OR Obtained [tiab])) AND (Stem cells [Mesh] OR Stromal cells [Mesh] OR Autologous progenitor cell* [tiab] OR Stromal vascular* [tiab] OR Regenerative cell* [tiab] OR Vascular stroma [tiab]))

Restriction: Only human

Search term Embase:

('adipose tissue':ab,ti OR 'adipocytes':ab,ti OR 'fat':ab,ti OR lipoaspirate*:ab,ti AND ('cell separation' OR isolat*:ab,ti OR dissociat*:ab,ti OR 'emulsification':ab,ti OR concentrat*:ab,ti OR digest*:ab,ti OR 'obtained':ab,ti) AND ('stem cells':ab,ti OR 'stromal cells':ab,ti OR 'autologous progenitor cell':ab,ti OR 'autologous progenitor cells':ab,ti OR 'stromal vascular':ab,ti OR 'stromal vascular fraction':ab,ti OR 'regenerative cell':ab,ti OR 'regenerative cells':ab,ti OR 'vascular stroma':ab,ti)) AND [embase]/lim NOT [medline]/lim AND 'article'/it

Restriction: Only EMBASE

Search term Cochrane Library:

(adipose tissue OR adipocytes OR fat OR lipoaspirate*) AND (cell separation OR Isolat* OR Dissociat* OR Emulsification OR Concentrat* OR Digest* OR Obtained) AND (stem cells OR stromal cells OR autologous progenitor cell* OR stromal vascular* OR regenerative cell* OR vascular stroma)

Acce

Table 3A. Duration, costs and procedure characteristics of intraoperative isolation procedures focusing on cSVF

Name	Author	Enzymatic/ Non- enzymatic (E/N)	Automatic/ Manual/ Semi (A/M/S)	Open/ closed (O/C)	Isolation details		Time (min)	Disposab le (D)/ reusable (R) cost (Dollar)	Volume process ed (ml)	Capacity (ml)	End volume (ml)	Maximum volume processed /maximum end volume
AIS	SundarRaj et al. 2015	E	A	С	Tissue digestion, heating and agitation, three- stage filter system (100 micron, 35 micron, 5 micron porosity)	-	133	-	-	500	10.8 [4- 20]	-
СНА	Aronowitz et al. 2013	E	S	С	Fat bag, adapter, centrifugation, shaking incubator and tissue digestion, cell strainer, cell counter	Collagenase	88+/2 3	D710	80-180	180	-	-
	Aronowitz et al. 2013						90 +/16	D1950	100-180	360	-	-
CYT	Aronowitz et al. 2016	E	A	С	Washing (lactated Ringer), tissue digestion and agitation, centrifugation	Celase/ Reagent A	89.4 [85- 93]	D2400 per 120-360 ml	126 [90- 150]	360	5 [5]	30
	Domenis et al. 2015					A	60	D	250	-	Pellet	-
	Lin et al. 2008						90	-	-	-	Pellet	-
GID- SVF2	Aronowitz et al. 2016	E	Μ	С	Disposable canister for harvesting, filtration, separation and concentration	GIDzyme-50	71.4 [68- 75]	D1000 per 20-120 ml	53.2 [32- 88]	120	7.2 [6- 9]	13.3
	Domenis et al. 2015					Liberase (collagenase mixture)	-	-	-	-	-	-
LIPOK	Aronowitz et al. 2013	E	S	С	1200 xg centrifugation (with a weight-mesh filter piston), celltibator	Collagenase	111+/ -18	D530	60-100	100	-	-
	Aronowitz et al. 2016					Time Machine accelerator	120.8 [99- 149]	D450 per 100 ml	71.4 [40–97]	400	20 [15- 25]	3.9
	Aronowitz et al. 2013						115+/ -13	D460	100-150	400	-	-
PNC	Aronowitz et al. 2016	E	М	0	Centrifugation, shaking incubator, clean bench, HEPA filter, UV-lamp	Collagenase	65.4 [59- 74]	D250 per 100 ml	105.6 [68-150]	800	12.2 [10.5- 15]	10
SEPAX	Güven et al. 2012	E	A	С	Tissue digestion, priming and straining, centrifugation, washing	0.15% NB6 GMP Grade Collagenase	90- 120	-	40-400	-	Pellet	-
TGCIS	Doi et al. 2012	E	A	С	Tissue digestion, centrifugation, washing, 700 xg centrifugation	0.075% collagenase	65	D	20-60	-	Pellet	-

AIS Automated Isolation System; CHA-station (CHA-Biotech); CYT Celution System Enzymatic (Cytori); GID SVF2 (GID Europe); LIPOK Lipokit System (Medi-khan); PNC Multi station (PNC); SEPAX Sepax (Biosafe); TGCIS Tissue Genesis Cell Isolation System (Tissue Genesis)

Table 3B. Duration, costs and procedure characteristics of intraoperative concentration procedures focusing on tSVF

Name	Author	Enzymatic/ Non- enzymatic (E/N)	Automatic/ Manual/ Semi (A/M/S)	Open/ closed (O/C)	Isolation details		Time (min)	Disposab le (D)/ reusable (R) cost (Dollar)	Volume process ed (ml)	Capacity (ml)	End volume (ml)	Maximum volume processed /maximum end volume
FAT	Van Dongen et al. 2016	N	М	0	3000 rpm (radius 9.5 cm) centrifugation, shuffling through a 1.4 mm hole connector, 3000 rpm (radius 9.5 cm) centrifugation	n/a	8-10	R	10	10	0.96 [0.75 - 1.75]	10.4
FAST	Domenis et al. 2015	N	М	-	Filterbag (120 micron filter), 400 xg centrifugation 1200 xg centrifugation, shuffling through a	n/a	-	-	-	-	10	-
FEF	Mashiko et al. 2016	Ν	М	0	connector with three small holes 30 times, 1200 xg centrifugation, fluid of decanting filtration (500-µm pore size) used	n/a	-	-	-	-	-	9.9+/-2.0
LIPOG	Bianchi et al. 2013	N	М	С	Filtering, decantation, stainless steel marbles to mix layers (oil, adipose tissue, blood, saline), washing, decantation, reversing devices, filtering	n/a	20	D	40-130	130	60-100	1.3
NANO	Tonnard et al. 2013	N	М	0	Shufling adipose tissue through a female-to- female luerlok 30 times, filtering	n/a	-	-	-	-	-	-
REF	Mashiko et al. 2016	N	М	0	1200 xg centrifugation, shuffling through a connector with three small holes 30 times, 1200 xg centrifugation, residual tissue of decanting filtration (500- μ m pore size) used	n/a	-	-	-	-	-	2.5+/-0.2
SF	Mashiko et al. 2016	N	М	0	1200 xg centrifugation, squeeze using automated slicer, 1200 xg centrifugation	n/a	-	-	-	-	-	2.1+/-0.2
SHUF5	Osinga et al. 2015	Ν	М	0	Shuffling lipoaspirate through female-to- female luerlok 30 times	n/a	5 sec.	-	10	-	-	-
SHUF30	Osinga et al. 2015	Ν	М	0	Shuffling lipoaspirate through female-to- female luerlok 30 times	n/a	30 sec.	-	10	-	-	-
STCELL	Milan et al.	Ν	Μ	С	1000 xg centrifugation	n/a	-	-	400	500	Pellet	-

FAT Fractionation of Adipose Tissue procedure; FAST Fastem Corios (Corios); FEF Filtrated fluid of emulsified fat; LIPOG Lipogems (Lipogems); NANO Nanofat procedure; REF Residual tissue of emulsified fat; SF Squeezed fat; SHUF5 Shuffling 5 times; SHUF30 Shuffling 30 times

T D

This article is protected by copyright. All rights reserved.

	Enz	zymatio	: is	olation	Non-	intraoperative	isolation					
	pro	cedure	•		proto	protocol						
Study	Ν	Cell	yield	SD	Ν	Cell yield	SD	Effect				
		x10^5	cells			x10^5 cells		size				
AIS, SundarRaj, 2015	11	1.17		0.5	11	1.15	0.30	0,07				
CYT, Domenis, 2015	9	11.7		5.0	16	6.7	3.30	1,52				
CYT, Lin, 2008	6	3.7		0.9	3	4.96	0.72	-1,75				
LIPOK, Domenis, 2015	9	5.0		3.0	16	6.7	3.30	-0,52				
SEPAX, Güven, 2012	6	2.6		1.2	6	1.6	0.90	1,11				
TGCIS, Doi, 2012	6	7.0		1.9	6	7.0	2.43	0,00				

AIS Automated Isolation System; CYT Celution System Enzymatic (Cytori); LIPOK Lipokit System (Medi-khan); SEPAX Sepax (Biosafe); TGCIS Tissue Genesis Cell Isolation System (Tissue Genesis)

Accepted

		Pro	cedure		Non-int				
		isolation protocol							
Study	Ν	%	viable	SD	Ν	%	viable	SD	Effect
		cells				cells			size
Enzymatic									
AIS, SundarRaj, 2015	11	97.5		2.8	11	97.3		1.5	0.13
CYT, Lin, 2008	3	89.2		1.1	3	90.8		1.3	-1.23
TGCIS, Doi, 2012	6	80.7		7.1	6	82.4		7.7	-0.22
Non-enzymatic									
FEF, Mashiko, 2016	10	39.3		9.1	10	93.8		1.2	-45.4
REF, Mashiko, 2016	10	90.6		2.8	10	93.8		1.2	-2.67
SF, Mashiko, 2016	10	89.9		4.6	10	93.8		1.2	-3.25
STCELL, Millan, 2014 ^a	3	87.7		8.9	3	74.5		20.1	0.66

Table 4B. Effect sizes of studies evaluating viable nucleated cells

^a No exact data described in text, data extracted from figures by authors JAD and AJT. AIS Automated Isolation System; CYT Celution System Enzymatic (Cytori); FEF Filtrated fluid of emulsified fat; REF Residual tissue of emulsified fat; SF Squeezed fat; STCELL StromaCell; TGCIS Tissue Genesis Cell Isolation System (Tissue Genesis)

Accepte

s	Studies Viability Flow cytomet			Flow	/ cyto	metry	of cu	ltured	ASC	s		CFU-F	Functio	Total			
		v lability	ry of SVF	CD 13	CD 29	CD 31	CD 44	CD 45	CD 73	CD 90	CD1 05	CD2 35a		Adipog enic	Osteog enic	Chondro genic	Score
	ronowitz et . 2013	1	1										1				3.00
	ronowitz et . 2016	1	1										1				3.00
	ianchi et al. 013	1	1										0	1/3	1/3	1/3	3.00
D	oi et al. 2012	1	1										0				2.00
	omenis et al. 015	0	1	1/9	1/9		1/9	1/9	1/9	1/9	1/9		1				2.78
	an Dongen al. 2016	1	0		1/9	1/9	1/9	1/9		1/9	1/9		1	1/3	1/3		3.33
	üven et al. 012	1	1		1/9		1/9		1/9	1/9	1/9		1	1/3	1/3	1/3	4.56
Li	n et al. 2008	1	1										1	1/3	1/3		3.67
	ashiko et al. 016	1	1										0				2.00
М	illan et al.	1	0				1/9		1/9	1/9	1/9		0				1.44
	singa et al. 015	1	0										1	1/3	1/3	1/3	3.00
	undarRaj et . 2015	1	1										1				3.00
	onnard et al. 013	0	1										0	1/3			1.33

Table 5. Modified IFATS index score for the measurement of adipose tissue-derived stromal vascular fraction

Accepted